HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.

AbstractAIMS:
To evaluate the implications of an Absorb bioresorbable vascular scaffold (Absorb BVS) on the morphology of the superficial plaques.
METHODS AND RESULTS:
Forty-six patients who underwent Absorb BVS implantation and 20 patients implanted with bare metal stents (BMS) who had serial optical coherence tomographic examination at baseline and follow-up were included in this analysis. The thin-capped fibroatheromas (TCFA) were identified in the device implantation regions and in the adjacent native coronary segments. Within all regions, circumferential locations of TCFA and calcific tissues were identified, and the neointimal thickness was measured at follow-up. At six to 12-month follow-up, only 8% of the TCFA detected at baseline were still present in the Absorb BVS and 27% in the BMS implantation segment (p=0.231). Sixty percent of the TCFA in native segments did not change their phenotype at follow-up. At short-term follow-up, significant reduction in the lumen area of the BMS was noted, which was higher compared to that reported in the Absorb BVS group (-2.11±1.97 mm2 vs. -1.34±0.99 mm2, p=0.026). In Absorb BVS, neointima tissue continued to develop at midterm follow-up (2.17±0.48 mm2 vs. 1.38±0.52 mm2, p<0.0001) and covered the underlying tissues without compromising the luminal dimensions (5.93±1.49 mm2 vs. 6.14±1.49 mm2, p=0.571) as it was accommodated by the expanded scaffold (8.28±1.74 mm2 vs. 7.67±1.28 mm2, p<0.0001).
CONCLUSIONS:
Neointimal tissue develops following either Absorb BVS or BMS implantation and shields lipid tissues. The neointimal response in the BMS causes a higher reduction of luminal dimensions compared to the Absorb BVS. Thus, Absorb BVS may have a value in the invasive re-capping of high-risk plaques.
AuthorsChristos V Bourantas, Patrick W Serruys, Shimpei Nakatani, Yao-Jun Zhang, Vasim Farooq, Roberto Diletti, Jurgen Ligthart, Alexander Sheehy, Robert-Jan M van Geuns, Dougal McClean, Bernard Chevalier, Stephan Windecker, Jacques Koolen, John Ormiston, Robert Whitbourn, Richard Rapoza, Susan Veldhof, Yoshinobu Onuma, Hector M Garcia-Garcia
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (EuroIntervention) Vol. 11 Issue 7 Pg. 746-56 (Nov 2015) ISSN: 1969-6213 [Electronic] France
PMID25308301 (Publication Type: Comparative Study, Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Metals
Topics
  • Absorbable Implants
  • Aged
  • Clinical Trials as Topic
  • Coronary Angiography
  • Coronary Artery Disease (diagnostic imaging, pathology, therapy)
  • Coronary Vessels (diagnostic imaging, pathology)
  • Female
  • Fibrosis
  • Follow-Up Studies
  • Humans
  • Male
  • Metals
  • Middle Aged
  • Neointima
  • Percutaneous Coronary Intervention (adverse effects, instrumentation)
  • Phenotype
  • Plaque, Atherosclerotic
  • Predictive Value of Tests
  • Prosthesis Design
  • Stents
  • Time Factors
  • Tomography, Optical Coherence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: